A collection of the latest publications on hyperhidrosis
 |
Related Articles |
A Comparison of Patient Reported Disease Severity and Sweat Measurements in Primary Focal Hyperhidrosis.
J Am Acad Dermatol. 2019 Apr 12;:
Authors: Gibbons M, Armbrecht E, Dudzinski J, Glaser DA
PMID: 30986479 [PubMed – as supplied by publisher]
 |
Related Articles |
Hyperhidrosis and Dysautonomia in a Patient with a History of Tetraplegia following Cervical Facet Radiofrequency Ablation: A Case Report.
PM R. 2019 Apr 15;:
Authors: Reddy R, Zardouz S, Rejai S, Chen J
Abstract
Chronic pain in those with spinal cord injury (SCI) can significantly impact quality of life, with prevalence ranging from 26%-96%1 . Treatment of chronic pain is notoriously challenging and unsatisfactory for providers and patients1,2 . Patients with traumatic SCI and fusion can develop adjacent-level degeneration3 . Facet-mediated pain can be treated with radiofrequency ablation (RFA) of the medial branch nerves that innervate the zygapophyseal joints4 .
PMID: 30985080 [PubMed – as supplied by publisher]
| Related Articles |
Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis
Skin Therapy Lett. 2019 Mar;24(2):1-3
Authors: Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK
Abstract
Hyperhidrosis is a condition characterized by excessive sweat production beyond which is physiologically necessary for thermal regulation. Affecting over 4.8% of the United States population, studies have shown that severe primary hyperhidrosis interferes with daily activities and can be considered intolerable, negatively impacting a patient’s quality of life. Glycopyrronium tosylate is a topical anticholinergic agent that reduces sweat production by blocking the activation of acetylcholine receptors in peripheral sweat glands. In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown to be an effective, safe and non-invasive treatment for patients suffering from primary hyperhidrosis. This review examines the clinical trials of topical glycopyrronium tosylate and its role in primary hyperhidrosis. Glycopyrronium tosylate was recently US FDA-approved (as of June 2018) to manage patients with primary axillary hyperhidrosis.
PMID: 30970203 [PubMed – as supplied by publisher]
 |
Related Articles |
Analysis of Contact Position for Subthalamic Nucleus Deep Brain Stimulation-Induced Hyperhidrosis.
Parkinsons Dis. 2019;2019:8180123
Authors: Yang C, Qiu Y, Wu X, Wang J, Wu Y, Hu X
Abstract
Objectives: To analyze the hyperhidrosis neural network structure induced by subthalamic nucleus (STN) – deep brain stimulation (DBS).
Materials and Methods: Patients with Parkinson’s disease treated with STN-DBS in Changhai Hospital between July 1, 2015, and December 1, 2016, were analyzed retrospectively. Using records of side effects of the intraoperative macrostimulation test, patients with skin sweats were selected as the sweating group. Based on the number of cases in the sweating group, the same number of patients was randomly selected from other STN-DBS patients without sweating to form the control group. The study standardized electrode position with Lead-DBS software to Montreal Neurological Institute (MNI) standard stereotactic space to compare the differences in three-dimensional coordinates of activated contacts between groups.
Results: Of 355 patients, 11 patients had sweats during intraoperative macrostimulation tests. There was no significant difference in the preoperative baseline information and the postoperative UPDRS-III improvement rate (Med-off, IPG-on) between groups. Contacts inducing sweat were more medial (X-axis) (11.02 ± 0.69 mm vs 11.98 ± 0.84 mm, P=0.00057) and more upward (Z-axis) (-7.15 ± 1.06 mm VS -7.98 ± 1.21 mm, P=0.032) than those of the control group. The straight-line distance between the center of the sweat contact and the nearest voxel of the red nucleus was closer than that of the control group (2.72 ± 0.65 mm VS 3.76 ± 0.85 mm, P=0.00012).
Conclusions: STN-DBS-induced sweat indicated that the contact was at superior medial of STN.
PMID: 30956787 [PubMed]
| Related Articles |
Intramedullary Spinal Cord Ganglioglioma Presenting as Hyperhidrosis: A Rare Case Report and literature Review.
World Neurosurg. 2019 Mar 20;:
Authors: Shi W, Zhao B, Yao J, Zhou Y, Tong M, Jing L, Wang G
Abstract
BACKGROUND: Hyperhidrosis is caused by sympathetic dysfunction of the central or peripheral nervous system. However, intramedullary spinal cord tumors presenting with hyperhidrosis as an initial symptom had been rarely reported in the literature.
CASE DESCRIPTION: This case involves an 18-year-old man who presented with abnormal enhanced sweating and flushing on the bilateral side of his face and neck that had persisted for 6 years. Magnetic resonance (MR) images revealed that, at the C7-T2 levels of the spinal cord, a large intramedullary tumor was involved in the cervico-thoracic region. The patient underwent gross total resection (GTR) of the tumor via the fluorescein-guided technique and intraoperative neurophysiological monitoring. The histopathological diagnosis revealed ganglioglioma. The symptoms gradually improved after the surgery, and the patient presented virtually complete remission at the end of an 18 months follow-up.
CONCLUSIONS: Few cases of intramedullary spinal cord tumors presenting as hyperhidrosis in clinical manifestation have been reported in the literature. Sympathetic irritation by the tumor, particularly in the location around the gray matter of the lateral spinal cord, may account for the hyperhidrosis as the initial symptom in present patient. Therefore, if a patient has autonomic dysfunction, the spine cord should be additionally examined using MR imaging.
PMID: 30904797 [PubMed – as supplied by publisher]
| Related Articles |
Dyshidrosis associated with diabetes mellitus: Hypohidrosis associated with diabetic neuropathy and compensated hyperhidrosis.
J Dermatol. 2019 Mar 12;:
Authors: Amano M, Namiki T, Munetsugu T, Nakamura M, Hashimoto T, Fujimoto T, Yokozeki H
PMID: 30859595 [PubMed – as supplied by publisher]
| Related Articles |
Does clip removal help for compensatory hyperhidrosis complicating thoracic sympathetic clipping?
Clin Auton Res. 2019 Mar 11;:
Authors: Kara M, Kose S, Ozkan B, Sertcakacilar G
Abstract
PMID: 30859345 [PubMed – as supplied by publisher]
| Related Articles |
Qbrexza – A glycopyrronium cloth for axillary hyperhidrosis.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):10-11
Authors:
Abstract
PMID: 30856158 [PubMed – in process]
| Related Articles |
The Treatment of Primary Focal Hyperhidrosis
Skin Therapy Lett. 2018 Jan;24(1):7
Authors: Wechter T, Feldman SR, Taylor SL
Abstract
Primary focal hyperhidrosis is a relatively common disease that has a significant impact on afflicted patient’s quality of life. The pathogenesis of the disease is thought to stem from increased cholinergic activity on eccrine sweat glands. Topical aluminum chloride based antiperspirants are good first-line agents for all affected body sites. Anticholinergic agents are emerging as effective topical alternatives. Iontophoresis passes an electrical current through the skin and is an excellent treatment option for palmoplantar disease. Botulinum toxin type A injections remain a mainstay second-line treatment. Local procedural advances including microwave thermolysis, laser therapy and focused ultrasound are emerging as safe and effective alternatives for refractory disease. Oral anticholinergics are generally well tolerated and can also be used for intractable disease. Last-line interventions include local surgical options and sympathectomy, though some patients may prefer permanent treatment. Further investigation of novel treatments as well as ways to optimize existing therapeutic options are needed.
PMID: 30817880 [PubMed – as supplied by publisher]
| Related Articles |
Cryoanalgesia with a CoolSense Device in Patients Treated with Botulinum Toxin-A for Palmar-Plantar Hyperhidrosis: A Self-Controlled Study.
Skin Appendage Disord. 2019 Feb;5(2):119-120
Authors: Kanni T, Agiasofitou E, Markantoni V, Tzanetakou V, Katoulis A, Gregoriou S, Rigopoulos D, Kontochristopoulos G
PMID: 30815449 [PubMed]